Stay updated on Pembrolizumab-Chemo, Olaparib Maint in EOC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab-Chemo, Olaparib Maint in EOC Clinical Trial page.

Latest updates to the Pembrolizumab-Chemo, Olaparib Maint in EOC Clinical Trial page
- CheckyesterdayChange DetectedThe page now displays Revision: v3.4.3. The previous Revision: v3.4.2 has been removed.SummaryDifference0.0%

- Check8 days agoNo Change Detected
- Check16 days agoNo Change Detected
- Check30 days agoChange DetectedFallopian tube cancer is now listed as a condition and the Genetic and Rare Diseases Information Center resource is added; the page version updated from v3.4.1 to v3.4.2.SummaryDifference0.1%

- Check37 days agoChange DetectedAdded Revision: v3.4.1 and removed Revision: v3.4.0.SummaryDifference0.0%

- Check44 days agoChange DetectedAdded a glossary toggle and updated metadata labels, including the 'Last Update Submitted that Met QC Criteria' entry, 'No FEAR Act Data' capitalization, and the revision/version to v3.4.0. These are minor UI/metadata updates and do not affect the study content or results; to avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check59 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4 on the study page; no substantive content changes are evident. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check80 days agoChange DetectedThe Locations section was expanded with new sites across the US, Canada, Europe, Australia, and other regions, while many of the previous locations were removed.SummaryDifference3%

Stay in the know with updates to Pembrolizumab-Chemo, Olaparib Maint in EOC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab-Chemo, Olaparib Maint in EOC Clinical Trial page.